Generic Biologics Bill From Waxman Offers Tax Incentives For Studies On Interchangeability
This article was originally published in The Pink Sheet Daily
Executive Summary
Bill permits comparable products as long as they have no clinically meaningful differences and share the "principal molecular structure features" as innovators.
You may also be interested in...
Generic Biologics Bill’s Key Battleground May Be Senate Health Committee
Reintroduced legislation drops tax credits for development of follow-ons. Sponsors see PDUFA reauthorization as ideal vehicle.
Generic Biologics Bill’s Key Battleground May Be Senate Health Committee
Reintroduced legislation drops tax credits for development of follow-ons. Sponsors see PDUFA reauthorization as ideal vehicle.
CTI Spin-Off Aims To Put Follow-On Biologics In The Clinic Within Two Years
Amgen products eyed as initial candidates, exec tells “The Pink Sheet” DAILY.